CytRx's Tamibarotene Eradicates Cancer in Advanced Acute Promyelocytic Leukemia After Failure of Other Therapies - FierceBiotech
Links shared publicly online about this topic.
- 1,002total visits
CytRx's Tamibarotene Eradicates Cancer in Advanced Acute Promyelocytic Leukemia After Failure of Other Therapies - FierceBiotech
View full resource at fiercebiotech.com
Most Recently Shared on July 23, 2010 at 1:26 am By:
CytRx's tamibarotene eradicates cancer in advanced acute promyelocytic leukemia after failure of other therapies. http://bit.ly/9z7AoH
NASDAQ notifies CytRx of non-compliance with minimum bid price requirement
news-medical.net — “CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that, as anticipated, on February 15, 2012, the Company was notified by The NASDAQ Stock Market that because the Company has not regained compliance with the $1.00 minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2), the Company's common stock would be subject to delisting from The NASDAQ Capital Market unless the Company requests a hearing before a NASDAQ Hearings Panel.” View full resource at news-medical.net
Most Recently Shared on February 18, 2012 at 12:09 pm By:
News-Medical.Net Health News and Oncology
Oncology News: NASDAQ notifies CytRx of non-compliance with minimum bid price requirement: CytRx Corporation, a ... http://t.co/Djdk9sau
Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors
news-medical.net — “CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.” View full resource at news-medical.net
Most Recently Shared on October 31, 2011 at 2:18 pm By:
Lung Cancer News: Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tu... http://t.co/djFEqt79
CytRx to Present at the Rodman & Renshaw 13th Annual Healthcare Conference - MarketWatch
marketwatch.com — “CytRx to Present at the Rodman & Renshaw 13th Annual Healthcare Conference - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on September 6, 2011 at 1:04 pm By:
CytRx to Present at the Rodman & Renshaw 13th Annual Healthcare Conference: ... announced that David Haen, the C... http://t.co/8cRmBGz
Building Blocks of a Biotech: CytRx Executives Talk About 3 Agents for Multiple Tumors
onclive.com — “Amid growing cost pressures in the pharmaceutical industry, many small companies are playing an increasingly active role in drug development.” View full resource at onclive.com
Most Recently Shared on July 29, 2011 at 2:35 pm By:
Building Blocks of a Biotech: CytRx Executives Talk About 3 Agents for Multiple Tumors http://t.co/EbRtH7e
CytRx prices underwritten public offering of common stock
news-medical.net — “CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has priced an underwritten public offering of 39,200,000 shares of common stock and warrants to purchase up to 39,200,000 shares of common stock at a combined public offering price of $0.52 per share and related warrant for gross proceeds of approximately $20.4 million.” View full resource at news-medical.net
Most Recently Shared on July 27, 2011 at 1:37 pm By:
News-Medical.Net Health News and Oncology
Oncology News: CytRx prices underwritten public offering of common stock: CytRx Corporation, a biopharmaceutical... http://bit.ly/o2RUJD
Cytrx Gets Rare Disease Status for Cancer Therapy - Drugs.com MedNews
drugs.com — “From Associated Press (July 5, 2011) CytRx Corp. received special regulatory designation for an experimental drug meant to treat a type of cancer that affects s” View full resource at drugs.com
Most Recently Shared on July 6, 2011 at 2:12 pm By:
Drugs and Devices OW OW Health
Cytrx Gets Rare Disease Status for Cancer Therapy: From Associated Press (July 5, 2011) WASHINGTON -- CytR... http://bit.ly/mWhsoF #drug
Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia
news-medical.net — “CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.” View full resource at news-medical.net
Most Recently Shared on June 13, 2011 at 7:13 pm By:
News-Medical.Net Health News and Oncology
Oncology News: Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymph... http://bit.ly/lBWVlJ
CytRx Reports Positive Preliminary Results from ENABLE Phase 2 Clinical Trial with Bafetinib in Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia - Drugs.com MedNews
drugs.com — “Bafetinib Demonstrates Clinical Activity in B-CLL Patients Who Failed Other Treatments Additional Trial Patients to Receive Bafetinib at Higher Doses as Importa” View full resource at drugs.com
Most Recently Shared on June 13, 2011 at 7:13 pm By:
Drugs and Devices OW OW Health
CytRx Reports Positive Preliminary Results from ENABLE Phase 2 Clinical Trial with Bafetinib in Patients w... http://bit.ly/kSJaco #drug
CytRx's INNO-206 Receives FDA Approval For Orphan Drug Designation For Pancreatic Cancer
medicalnewstoday.com — “CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug desig” View full resource at medicalnewstoday.com
Most Recently Shared on May 3, 2011 at 5:05 pm By:
MNT Pancreatic Can Health News
CytRx's INNO-206 Receives FDA Approval For Orphan Drug Designation For Pancreatic Cancer http://mnt.to/3Vmg #pancreaticcancer
FDA approves orphan drug designation for Cytrx--™s INNO-206 to treat pancreatic cancer
news-medical.net — “CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.” View full resource at news-medical.net
Most Recently Shared on April 28, 2011 at 6:40 pm By:
Prostate Cancer: FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer: CytRx Cor... http://bit.ly/mqBZ4e
Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL
news-medical.net — “CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.” View full resource at news-medical.net
Most Recently Shared on April 19, 2011 at 10:55 am By:
Lung Cancer News: Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL: CytRx... http://bit.ly/fy8AMV
CytRx Announces the Publication of a Peer-Reviewed Case Report Documenting Tamibarotene's Successful Elimination of Recurrent Advanced-Stage Leukemia - Drugs.com MedNews
drugs.com — “Journal of Clinical Oncology Report Emphasizes Potent Activity of Tamibarotene Supports Company s Ongoing Clinical Trial in Advanced Lung Cancer Representing Mu” View full resource at drugs.com
Most Recently Shared on April 18, 2011 at 5:15 pm By:
Drugs and Devices OW OW Health
CytRx Announces the Publication of a Peer-Reviewed Case Report Documenting Tamibarotene's Successful Elimi... http://bit.ly/enibFh #drug
CytRx to present bafetinib preclinical study results at AACR Annual Meeting
news-medical.net — “CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research 102nd Annual Meeting in Orlando, Florida.” View full resource at news-medical.net
Most Recently Shared on March 29, 2011 at 9:22 am By:
Lung Cancer News: CytRx to present bafetinib preclinical study results at AACR Annual Meeting: CytRx Corporation... http://bit.ly/gTDfL1
CytRx's Bafetinib Demonstrates Ability to Prevent Cancer-Related Bone Loss - Drugs.com MedNews
drugs.com — “Preclinical studies show that low concentrations of bafetinib significantly inhibited the condition that causes cancer-related bone deterioration Feb 8, 2011 -” View full resource at drugs.com
Most Recently Shared on February 10, 2011 at 9:01 pm By:
Drugs and Devices OW OW Health
CytRx's Bafetinib Demonstrates Ability to Prevent Cancer-Related Bone Loss: – Preclinical studies show tha... http://bit.ly/fPHUcf #drug
CytRx's bafetinib helps reduce skeletal complications in cancer patients
news-medical.net — “CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies show that bafetinib may be useful in preventing bone loss in cancer patients who are at high risk for this event.” View full resource at news-medical.net
Most Recently Shared on February 9, 2011 at 9:14 am By:
Lung Cancer News: CytRx's bafetinib helps reduce skeletal complications in cancer patients: CytRx Corporation, a... http://bit.ly/i7T8ex
Advertisement
